BIBCL.BO · BSE
BHARAT IMMUNOLOGICALS & BIOLOG
₹13.25
-1.27% (-₹0.17)
Prev. close
₹13.42
Volume
44,025
As of
24 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About BHARAT IMMUNOLOGICALS & BIOLOG
Bharat Immunologicals & Biologicals Corporation Limited, a biotechnology company, engages in the manufacture and sale of pharmaceutical products in India. It offers oral polio vaccines, zinc tablets, diarrhea management kits, and BIB sweet tablets. The company was incorporated in 1989 and is based in Bulandshahr, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Dhananjay Kumar Tiwary
Headquarters
Bulandshahr
Website
bibcol.sciencecentral.inExchange
View on BSE ↗Key stats
Market cap
₹57.21 Cr
EPS (TTM)
₹-2.73
Beta (1Y · daily vs NIFTY 50)
0.86
Beta (5Y · monthly vs NIFTY 50)
0.98
Shares float
1.76 Cr
Financial Performance
01 · Financials
FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 |
|---|---|---|
| ₹78.39 Cr | ₹44.61 Cr | |
| EBITDA | ₹-4.37 Cr | ₹-15.11 Cr |
| ₹-8.75 Cr | ₹-16.64 Cr | |
| Diluted EPS | ₹-2.03 | ₹-3.85 |
09 · Balance Sheet
Annual
| Line item | FY22 | FY23 |
|---|---|---|
| ₹212.73 Cr | ₹188.65 Cr | |
| ₹77.89 Cr | ₹70.22 Cr | |
| Stockholders' equity | ₹105.35 Cr | ₹88.21 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 |
|---|---|---|
| ₹-42.12 Cr | ₹10.89 Cr | |
| Investing cash flow | ₹53.12 L | ₹46.22 L |
| Financing cash flow | ₹45.00 Cr | ₹-14.71 Cr |
| End cash position | ₹4.64 Cr | ₹1.29 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| BHARAT IMMUNOLOGICALS & BIOLOG | ₹57.95 Cr | ₹13.42 | — | 0.66 | -18.9% | 0.80 | -43.1% | -37.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 25
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.